Sign In
Buy DTIL
$6.04
-0.280 (-4.43%)
At Close: Jun 03, 2026
Precision BioSciences Appoints Stanley R. Frankel, M.D.
07:06am, Monday, 12'th Apr 2021
DURHAM, N.C.--(BUSINESS WIRE)--Stanley R. Frankel, M.D. has been appointed to the Board of Directors for Precision BioSciences.
Precision BioSciences to Participate in the Truist Securities 2021 Life Sciences Virtual Series
04:05pm, Friday, 09'th Apr 2021
DURHAM, N.C.--(BUSINESS WIRE)--Derek Jantz, CSO and Co-Founder of Precision BioSciences, will participate in a fireside chat at Truist Securities Life Sciences Virtual Series.
Precision BioSciences Announces CEO Transition Plan
08:35am, Tuesday, 06'th Apr 2021
Begins Search for Next Chief Executive Officer Begins Search for Next Chief Executive Officer
Precision BioSciences to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day
07:00am, Monday, 29'th Mar 2021
DURHAM, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies wi
Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates
09:28am, Thursday, 18'th Mar 2021
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 12.00% and 136.97%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the sto
Recap: Precision BioSciences Q4 Earnings
07:34am, Thursday, 18'th Mar 2021
Shares of Precision BioSciences (NASDAQ:DTIL) moved higher by 2.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 22.22% year over year to
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021
07:00am, Friday, 12'th Mar 2021
DURHAM, N.C., March 12, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company, today announced it will publish fourth quarter and fiscal year 2020
TransCode Therapeutics Starts $29 Million IPO Effort
04:55pm, Sunday, 07'th Mar 2021
TransCode Therapeutics Starts $29 Million IPO Effort
Will Precision BioSciences (DTIL) Report Negative Q4 Earnings? What You Should Know
01:38pm, Tuesday, 02'nd Mar 2021
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precision Bio's ARCUS Gene Editing Platform Is Safe, Durable; Long-Term Animal Study Shows
08:32am, Friday, 19'th Feb 2021
Precision BioSciences Inc (NASDAQ: DTIL) has announced three-year follow-up data showing long-term stable reduction of low-density lipoprotein (LDL) cholesterol levels in nonhuman primates (NHPs)
Study Led by Gene Therapy Program at the University of Pennsylvania Published in Molecular Therapy Study Led by Gene Therapy Program at the University of Pennsylvania Published in Molecular Therapy
DTIL Stock Price Increases Over 19% Pre-Market: Why It Happened
08:13am, Thursday, 21'st Jan 2021
The stock price of Precision BioSciences Inc (NASDAQ: DTIL) has increased by over 19% pre-market today. This is why it happened.
Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA Nod
10:32am, Wednesday, 20'th Jan 2021
The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.
Phase 1 clinical trial of PBCAR19B for patients with relapsed/refractory NHL expected to begin by mid-2021 Phase 1 clinical trial of PBCAR19B for patients with relapsed/refractory NHL expected to begi
I've Joined Eli Lilly In Buying Precision BioSciences Stock
01:25am, Tuesday, 15'th Dec 2020
DTIL has three business lines, all of which include important collaborations with large companies. Recent results in CAR-T therapies have been very encouraging.
